Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

Detalles Bibliográficos
Autores principales: De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Caputo, R., Cianniello, D., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103531/
https://www.ncbi.nlm.nih.gov/pubmed/33926709
http://dx.doi.org/10.1016/j.esmoop.2021.100097
_version_ 1783689325698875392
author De Angelis, C.
Bruzzese, D.
Bernardo, A.
Baldini, E.
Leo, L.
Fabi, A.
Gamucci, T.
De Placido, P.
Poggio, F.
Russo, S.
Forestieri, V.
Lauria, R.
De Santo, I.
Caputo, R.
Cianniello, D.
Michelotti, A.
Del Mastro, L.
De Laurentiis, M.
Giuliano, M.
De Placido, S.
Arpino, G.
author_facet De Angelis, C.
Bruzzese, D.
Bernardo, A.
Baldini, E.
Leo, L.
Fabi, A.
Gamucci, T.
De Placido, P.
Poggio, F.
Russo, S.
Forestieri, V.
Lauria, R.
De Santo, I.
Caputo, R.
Cianniello, D.
Michelotti, A.
Del Mastro, L.
De Laurentiis, M.
Giuliano, M.
De Placido, S.
Arpino, G.
author_sort De Angelis, C.
collection PubMed
description
format Online
Article
Text
id pubmed-8103531
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81035312021-05-14 Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054] De Angelis, C. Bruzzese, D. Bernardo, A. Baldini, E. Leo, L. Fabi, A. Gamucci, T. De Placido, P. Poggio, F. Russo, S. Forestieri, V. Lauria, R. De Santo, I. Caputo, R. Cianniello, D. Michelotti, A. Del Mastro, L. De Laurentiis, M. Giuliano, M. De Placido, S. Arpino, G. ESMO Open Corrigendum Elsevier 2021-04-26 /pmc/articles/PMC8103531/ /pubmed/33926709 http://dx.doi.org/10.1016/j.esmoop.2021.100097 Text en © 2021 The Author(s)
spellingShingle Corrigendum
De Angelis, C.
Bruzzese, D.
Bernardo, A.
Baldini, E.
Leo, L.
Fabi, A.
Gamucci, T.
De Placido, P.
Poggio, F.
Russo, S.
Forestieri, V.
Lauria, R.
De Santo, I.
Caputo, R.
Cianniello, D.
Michelotti, A.
Del Mastro, L.
De Laurentiis, M.
Giuliano, M.
De Placido, S.
Arpino, G.
Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
title Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
title_full Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
title_fullStr Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
title_full_unstemmed Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
title_short Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
title_sort corrigendum to ‘eribulin in combination with bevacizumab as second-line treatment for her2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase ii, single arm trial (gim11-bergi)’: [esmo open volume 6, issue 2, april 2021, 100054]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103531/
https://www.ncbi.nlm.nih.gov/pubmed/33926709
http://dx.doi.org/10.1016/j.esmoop.2021.100097
work_keys_str_mv AT deangelisc corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT bruzzesed corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT bernardoa corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT baldinie corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT leol corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT fabia corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT gamuccit corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT deplacidop corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT poggiof corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT russos corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT forestieriv corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT lauriar corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT desantoi corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT caputor corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT cianniellod corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT michelottia corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT delmastrol corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT delaurentiism corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT giulianom corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT deplacidos corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054
AT arpinog corrigendumtoeribulinincombinationwithbevacizumabassecondlinetreatmentforher2negativemetastaticbreastcancerprogressingafterfirstlinetherapywithpaclitaxelandbevacizumabamulticenterphaseiisinglearmtrialgim11bergiesmoopenvolume6issue2april2021100054

Ejemplares similares